Effects of incretin-based therapies on renal function

European Journal of Pharmacology

Volumn 818, Issue , 2018, Pages 103-109

  Tsimihodimos, Vasilis ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Albuminuria; Diabetic nephropathy; Glomerular filtration rate; Incretins; Natriuresis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARBOHYDRATE METABOLISM; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RISK REDUCTION; AGONISTS; ANIMAL; KIDNEY; PHYSIOLOGY;

ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; INCRETINS; KIDNEY;

EID: 85038859145     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.10.049     Document Type: Review

References (77)

1. Aroor, A., Zuberek, M., Duta, C., Meuth, A., Sowers, J.R., Whaley-Connell, A., Nistala, R., Angiotensin II stimulation of DPP4 activity regulates megalin in the proximal tubules. Int. J. Mol. Sci., 17, 2016.
2. Asmar, A., Simonsen, L., Asmar, M., Madsbad, S., Holst, J.J., Frandsen, E., Moro, C., Jonassen, T., Bulow, J., Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am. J. Physiol. Endocrinol. Metab. 308 (2015), E641–E649.
3. Asmar, A., Simonsen, L., Asmar, M., Madsbad, S., Holst, J.J., Frandsen, E., Moro, C., Sorensen, C.M., Jonassen, T., Bulow, J., Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. Am. J. Physiol. Endocrinol. Metab. 310 (2016), E744–E753.
4. Barale, C., Buracco, S., Cavalot, F., Frascaroli, C., Guerrasio, A., Russo, I., Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb. Haemost. 117 (2017), 1115–1128.
5. Bethel, M.A., Engel, S.S., Green, J.B., Huang, Z., Josse, R.G., Kaufman, K.D., Standl, E., Suryawanshi, S., Van de Werf, F., McGuire, D.K., Peterson, E.D., Holman, R.R., Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care 40 (2017), 494–501.
6. Birnbaum, Y., Bajaj, M., Qian, J., Ye, Y., Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res. Care, 4, 2016, e000227.
7. 3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am. J. Physiol. Ren. Physiol. 297 (2009), F1647–F1655.
8. Chambers, A.P., Sorrell, J.E., Haller, A., Roelofs, K., Hutch, C.R., Kim, K.S., Gutierrez-Aguilar, R., Li, B., Drucker, D.J., D'Alessio, D.A., Seeley, R.J., Sandoval, D.A., The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab., 25(927–934), 2017, e923.
9. Chen, L.H., Advani, S.L., Thai, K., Kabir, M.G., Sood, M.M., Gibson, I.W., Yuen, D.A., Connelly, K.A., Marsden, P.A., Kelly, D.J., Gilbert, R.E., Advani, A., SDF-1/CXCR4 signaling preserves microvascular integrity and renal function in chronic kidney disease. PLoS One, 9, 2014, e92227.
10. Chen, Y.T., Tsai, T.H., Yang, C.C., Sun, C.K., Chang, L.T., Chen, H.H., Chang, C.L., Sung, P.H., Zhen, Y.Y., Leu, S., Chang, H.W., Chen, Y.L., Yip, H.K., Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J. Transl. Med., 11, 2013, 270.
11. Crajoinas, R.O., Oricchio, F.T., Pessoa, T.D., Pacheco, B.P., Lessa, L.M., Malnic, G., Girardi, A.C., Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol. Ren. Physiol. 301 (2011), F355–F363.
12. Davidson, J.A., Brett, J., Falahati, A., Scott, D., Mild renal impairment and the efficacy and safety of liraglutide. Endocr. Pract. 17 (2011), 345–355.
13. Davies, M.J., Bain, S.C., Atkin, S.L., Rossing, P., Scott, D., Shamkhalova, M.S., Bosch-Traberg, H., Syren, A., Umpierrez, G.E., Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients With type 2 diabetes and moderate renal impairment (LIRA-renal): a randomized clinical trial. Diabetes Care 39 (2016), 222–230.
14. de Lucas, M.D.G., Bueno, B.A., Sierra, J.O., Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease. Eur. J. Intern. Med., 2017.
15. Edwards, C.M., Todd, J.F., Mahmoudi, M., Wang, Z., Wang, R.M., Ghatei, M.A., Bloom, S.R., Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 48 (1999), 86–93.
16. Fujita, H., Taniai, H., Murayama, H., Ohshiro, H., Hayashi, H., Sato, S., Kikuchi, N., Komatsu, T., Komatsu, K., Narita, T., Yamada, Y., DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy. Endocr. J. 61 (2014), 159–166.
17. 3 in rat renal proximal tubule. Am. J. Physiol. Ren. Physiol. 294 (2008), F414–F422.
18. 4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am. J. Physiol. Ren. Physiol. 303 (2012), F681–F688.
19. Groop, P.H., Cooper, M.E., Perkovic, V., Emser, A., Woerle, H.J., von Eynatten, M., Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36 (2013), 3460–3468.
20. Groop, P.H., Cooper, M.E., Perkovic, V., Hocher, B., Kanasaki, K., Haneda, M., Schernthaner, G., Sharma, K., Stanton, R.C., Toto, R., Cescutti, J., Gordat, M., Meinicke, T., Koitka-Weber, A., Thiemann, S., von Eynatten, M., Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes. Metab., 2017.
21. Gutzwiller, J.P., Tschopp, S., Bock, A., Zehnder, C.E., Huber, A.R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., Beglinger, C., Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89 (2004), 3055–3061.
22. Hansen, L., Deacon, C.F., Orskov, C., Holst, J.J., Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140 (1999), 5356–5363.
23. Hattori, S., Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr. J. 58 (2011), 69–73.
24. Heerspink, H.J., Kropelin, T.F., Hoekman, J., de Zeeuw, D., Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J. Am. Soc. Nephrol. 26 (2015), 2055–2064.
25. Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., Takayanagi, R., GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 61 (2012), 1422–1434.
26. Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., Nangaku, M., Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am. J. Physiol. Ren. Physiol. 308 (2015), F878–F887.
27. Hirata, T., Inukai, K., Morimoto, J., Katayama, S., Ishida, H., Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes. Prim. Care Diabetes 8 (2014), 265–270.
28. Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., Zhang, J.H., Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow. Metab. 32 (2012), 2201–2210.
29. Jackson, E.K., Context-dependent effects of dipeptidyl peptidase 4 inhibitors. Curr. Opin. Nephrol. Hypertens. 26 (2017), 83–90.
30. Jackson, E.K., Kochanek, S.J., Gillespie, D.G., Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 60 (2012), 757–764.
31. Kageyama, K., Yamagata, S., Akimoto, K., Sugiyama, A., Murasawa, S., Suda, T., Action of glucagon-like peptide 1 and glucose levels on corticotropin-releasing factor and vasopressin gene expression in rat hypothalamic 4B cells. Mol. Cell. Endocrinol. 362 (2012), 221–226.
32. Kettmann, U., Humbel, B., Holzhausen, H.J., Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochem. 92 (1992), 225–227.
33. Kim, M., Platt, M.J., Shibasaki, T., Quaggin, S.E., Backx, P.H., Seino, S., Simpson, J.A., Drucker, D.J., GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19 (2013), 567–575.
34. Kodera, R., Shikata, K., Kataoka, H.U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., Sato, C., Ogawa, D., Makino, H., Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54 (2011), 965–978.
35. Kutina, A.V., Golosova, D.V., Marina, A.S., Shakhmatova, E.I., Natochin, Y.V., Role of vasopressin in the regulation of renal sodium excretion: interaction with glucagon-like peptide-1. J. Neuroendocrinol., 28, 2016.
36. Kutina, A.V., Marina, A.S., Shakhmatova, E.I., Natochin, Y.V., Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic. Clin. Exp. Pharmacol. Physiol. 40 (2013), 510–517.
37. Lee, J.W., Chou, C.L., Knepper, M.A., Deep sequencing in microdissected renal tubules identifies nephron segment-specific transcriptomes. J. Am. Soc. Nephrol. 26 (2015), 2669–2677.
38. Leheste, J.R., Rolinski, B., Vorum, H., Hilpert, J., Nykjaer, A., Jacobsen, C., Aucouturier, P., Moskaug, J.O., Otto, A., Christensen, E.I., Willnow, T.E., Megalin knockout mice as an animal model of low molecular weight proteinuria. Am. J. Pathol. 155 (1999), 1361–1370.
39. Lovshin, J.A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., Drucker, D.J., Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38 (2015), 132–139.
40. Lovshin, J.A., Rajasekeran, H., Lytvyn, Y., Lovblom, L.E., Khan, S., Alemu, R., Locke, A., Lai, V., He, H., Hittle, L., Wang, W., Drucker, D.J., Cherney, D.Z.I., Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha1-67 in patients with type 2 diabetes. Diabetes Care 40 (2017), 1073–1081.
41. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M.L., Woo, V., Hansen, O., Holst, A.G., Pettersson, J., Vilsboll, T., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375 (2016), 1834–1844.
42. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., Steinberg, W.M., Stockner, M., Zinman, B., Bergenstal, R.M., Buse, J.B., Committee, L.S., Investigators, L.T., Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375 (2016), 311–322.
43. Matheeussen, V., Jungraithmayr, W., De Meester, I., Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol. Ther. 136 (2012), 267–282.
44. Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., Gallwitz, B., Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53 (2004), 654–662.
45. Mosenzon, O., Leibowitz, G., Bhatt, D.L., Cahn, A., Hirshberg, B., Wei, C., Im, K., Rozenberg, A., Yanuv, I., Stahre, C., Ray, K.K., Iqbal, N., Braunwald, E., Scirica, B.M., Raz, I., Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care 40 (2017), 69–76.
46. Muskiet, M.H., Tonneijck, L., Smits, M.M., Kramer, M.H., Diamant, M., Joles, J.A., van Raalte, D.H., Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes. Metab. 18 (2016), 178–185.
47. Naslund, E., Gutniak, M., Skogar, S., Rossner, S., Hellstrom, P.M., Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am. J. Clin. Nutr. 68 (1998), 525–530.
48. 4. Am. J. Physiol. Ren. Physiol. 312 (2017), F661–F670.
49. Pawaskar, M., Tuttle, K.R., Li, Q., Best, J.H., Anderson, P.W., Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine. Ann. Pharmacother. 48 (2014), 571–576.
50. Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., Lawson, F.C., Ping, L., Wei, X., Lewis, E.F., Maggioni, A.P., McMurray, J.J., Probstfield, J.L., Riddle, M.C., Solomon, S.D., Tardif, J.C., Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373 (2015), 2247–2257.
51. Pyke, C., Knudsen, L.B., The glucagon-like peptide-1 receptor—or not?. Endocrinology 154 (2013), 4–8.
52. Rieg, T., Gerasimova, M., Murray, F., Masuda, T., Tang, T., Rose, M., Drucker, D.J., Vallon, V., Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am. J. Physiol. Ren. Physiol. 303 (2012), F963–F971.
53. Robinson, E., Tate, M., Lockhart, S., McPeake, C., O'Neill, K.M., Edgar, K.S., Calderwood, D., Green, B.D., McDermott, B.J., Grieve, D.J., Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling. Cardiovasc. Diabetol., 15, 2016, 65.
54. Sakata, K., Hayakawa, M., Yano, Y., Tamaki, N., Yokota, N., Eto, T., Watanabe, R., Hirayama, N., Matsuo, T., Kuroki, K., Sagara, S., Mishima, O., Koga, M., Nagata, N., Nishino, Y., Kitamura, K., Kario, K., Takeuchi, M., Yamagishi, S., Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab. Res. Rev. 29 (2013), 624–630.
55. Schirra, J., Kuwert, P., Wank, U., Leicht, P., Arnold, R., Goke, B., Katschinski, M., Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc. Assoc. Am. Physicians 109 (1997), 84–97.
56. Schlatter, P., Beglinger, C., Drewe, J., Gutmann, H., Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul. Pept. 141 (2007), 120–128.
57. Shi, S., Srivastava, S.P., Kanasaki, M., He, J., Kitada, M., Nagai, T., Nitta, K., Takagi, S., Kanasaki, K., Koya, D., Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney Int. 88 (2015), 479–489.
58. Siddiqi, F.S., Chen, L.H., Advani, S.L., Thai, K., Batchu, S.N., Alghamdi, T.A., White, K.E., Sood, M.M., Gibson, I.W., Connelly, K.A., Marsden, P.A., Advani, A., CXCR4 promotes renal tubular cell survival in male diabetic rats: implications for ligand inactivation in the human kidney. Endocrinology 156 (2015), 1121–1132.
59. Skov, J., Effects of GLP-1 in the kidney. Rev. Endocr. Metab. Disord. 15 (2014), 197–207.
60. Skov, J., Dejgaard, A., Frokiaer, J., Holst, J.J., Jonassen, T., Rittig, S., Christiansen, J.S., Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 98 (2013), E664–E671.
61. Skov, J., Pedersen, M., Holst, J.J., Madsen, B., Goetze, J.P., Rittig, S., Jonassen, T., Frokiaer, J., Dejgaard, A., Christiansen, J.S., Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes. Metab. 18 (2016), 581–589.
62. Takagaki, Y., Koya, D., Kanasaki, K., Dipeptidyl peptidase-4 inhibition and renoprotection: the role of antifibrotic effects. Curr. Opin. Nephrol. Hypertens. 26 (2017), 56–66.
63. Takasawa, W., Ohnuma, K., Hatano, R., Endo, Y., Dang, N.H., Morimoto, C., Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem. Biophys. Res. Commun. 401 (2010), 7–12.
64. Takashima, S., Fujita, H., Fujishima, H., Shimizu, T., Sato, T., Morii, T., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D.J., Seino, Y., Yamada, Y., Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 90 (2016), 783–796.
65. Tani, S., Nagao, K., Hirayama, A., Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study. Am. J. Cardiovasc. Drugs 13 (2013), 443–450.
66. Thomas, M.C., The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab. 43:Suppl 1 (2017), 2S20–22S27.
67. Tomas, E., Stanojevic, V., McManus, K., Khatri, A., Everill, P., Bachovchin, W.W., Habener, J.F., GLP-1(32-36)amide pentapeptide increases basal energy expenditure and inhibits weight gain in obese mice. Diabetes 64 (2015), 2409–2419.
68. Tonneijck, L., Smits, M.M., Muskiet, M.H., Hoekstra, T., Kramer, M.H., Danser, A.H., Diamant, M., Joles, J.A., van Raalte, D.H., Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia 59 (2016), 1412–1421.
69. Tonneijck, L., Smits, M.M., Muskiet, M.H., Hoekstra, T., Kramer, M.H., Danser, A.H., Ter Wee, P.M., Diamant, M., Joles, J.A., van Raalte, D.H., Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 39 (2016), 2042–2050.
70. Tuttle, K.R., McKinney, T.D., Davidson, J.A., Anglin, G., Harper, K.D., Botros, F.T., Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes. Metab. 19 (2017), 436–441.
71. Udell, J.A., Bhatt, D.L., Braunwald, E., Cavender, M.A., Mosenzon, O., Steg, P.G., Davidson, J.A., Nicolau, J.C., Corbalan, R., Hirshberg, B., Frederich, R., Im, K., Umez-Eronini, A.A., He, P., McGuire, D.K., Leiter, L.A., Raz, I., Scirica, B.M., Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 38 (2015), 696–705.
72. von Scholten, B.J., Hansen, T.W., Goetze, J.P., Persson, F., Rossing, P., Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J. Diabetes Complicat. 29 (2015), 670–674.
73. von Scholten, B.J., Lajer, M., Goetze, J.P., Persson, F., Rossing, P., Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet. Med. 32 (2015), 343–352.
74. von Scholten, B.J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T.W., Rossing, P., The effect of liraglutide on renal function: a randomized clinical trial. Diabetes Obes. Metab. 19 (2017), 239–247.
75. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O.E., Woerle, H.J., Broedl, U.C., Zinman, B., Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375 (2016), 323–334.
76. Zavattaro, M., Caputo, M., Sama, M.T., Mele, C., Chasseur, L., Marzullo, P., Pagano, L., Mauri, M.G., Ponziani, M.C., Aimaretti, G., Prodam, F., One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 50 (2015), 620–626.
77. Zeisberg, M., Zeisberg, E.M., Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney Int. 88 (2015), 429–431.